株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Irribow (過敏性腸症候群治療薬) - 2023年までの予測と市場分析

Irribow (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 325977
出版日 ページ情報 英文 42 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
Irribow (過敏性腸症候群治療薬) - 2023年までの予測と市場分析 Irribow (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023
出版日: 2014年12月31日 ページ情報: 英文 42 Pages
概要

当レポートでは、過敏性腸症候群の治療薬であるIrribowについて調査しており、過敏性腸症候群の概要や治療薬の競合動向、製品情報、売上予測などを提供しています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因と病態生理学
    • 病因
    • 病態生理学
  • 分類
  • 症状
  • 予後
  • 生活の質 (QOL)

第4章 疾患の管理

  • 疾患と治療の概要
    • 診断
    • 治療ガイドラインと主な処方薬
    • 臨床診療

第5章 競合評価

  • 概要

第6章 Irribow (ラモセトロン)

  • 概要
  • 有効性
  • 安全性
  • SWOT分析
  • 予測

第7章 付録

目次
Product Code: GDHC520DFR

Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naive, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.

Irribow (ramosetron) is a product that was developed and is marketed by Astellas Pharma, and is available only in Japan for the treatment of males with IBS-D. In July 2014, Astellas announced that it had submitted an sNDA for Irribow for the treatment of females with IBS-D to the Ministry of Health, Labor and Welfare (MHLW) in Japan (Astellas Pharma, press release, July 14, 2014).

Scope

  • Overview of IBS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Irribow including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Irribow for the top country from 2013 to 2023.
  • Sales information covered for Japan.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for IBS.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of Irribow performance.
  • Obtain sales forecast for Irribow from 2013-2023 in top country (Japan).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Irribow (ramosetron)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety

6.4. SWOT Analysis

  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed IBS Patients
    • 7.4.2. General Pricing Assumptions
    • 7.4.3. Individual Drug Assumptions
    • 7.4.4. Generic Erosion
  • 7.5. Primary Research - KOLs Interviewed for This Report
  • 7.6. Primary Research - Prescriber Survey
  • 7.7. About the Authors
    • 7.7.1. Analyst
    • 7.7.2. Therapy Area Director
    • 7.7.3. Global Head of Healthcare
  • 7.8. About GlobalData
  • 7.9. Disclaimer

List of Tables

  • Table 1: Common Symptoms of IBS
  • Table 2: Summary of the Various Diagnostic Criteria Used for the Diagnosis of IBS
  • Table 3: Treatment Guidelines for IBS
  • Table 4: Leading Prescribed Drugs for IBS by Predominant Symptoms in the 7MM, 2014†
  • Table 5: Leading Branded Treatments for IBS, 2014
  • Table 6: Product Profile - Irribow
  • Table 7: Irribow SWOT Analysis, 2014
  • Table 8: Global IBS Sales Forecasts ($m) for Irribow, 2013-2023
  • Table 9: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Summary of Pharmacotherapies Used to Treat IBS
Back to Top